Specifically, this study showed an OS of 17.1 months with nivolumab + ipilimumab (95% CI 15.0–20.1) compared to CT, which was 14.9 months (95% CI 12.7–16.7) for patients with NSCLC with a PD-L1 expression level of 1% or more (p = 0.007). The gene discussed is CD274; the disease is non-small cell lung carcinoma.